This was part of the VaccGene study, which aimed to identify genetic variants associated with differential response to vaccination in infancy but with ethical approval to undertake analyses to examine the effect of iron status on infection susceptibility. Details of the study design are described elsewhere37 (link). Infants between the ages of 6 and 18 months living in the Banfora region of Burkina Faso were recruited into a phase 1–2b clinical trial to test the safety, immunogenicity and efficacy of an experimental heterologous viral-vectored prime-boost liver-stage malaria vaccine37 (link). Serum ferritin (Chemiluminescent Microparticle Immunoassay, Abbott Architect), hepcidin (DRG Hepcidin 25 (bioactive) High Sensitive ELISA kit (DRG International)), CRP (Multigent CRP Vario assay, Abbott Architect), hemoglobin (Coulter analyzer, Beckman Coulter) and malaria parasitemia (Giemsa-stained thick and thin blood films) were measured at a single time point. Genotyping of sickle cell trait in the VaccGene study is described below.
Free full text: Click here